Frankfurt - Delayed Quote EUR

Akeso, Inc. (4RY.F)

9.40
+0.05
+(0.53%)
At close: May 16 at 7:07:06 PM GMT+2
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for 4RY.F

Recent News: 4RY.F

View More
Summit Therapeutics Q1 Loss Narrower Than Expected, Sales Nil

Summit Therapeutics Q1 Loss Narrower Than Expected, Sales Nil
Zacks 15 days ago
Exploring High Growth Tech Stocks in Asia April 2025

Exploring High Growth Tech Stocks in Asia April 2025
Simply Wall St. 19 days ago
Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today

Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today
Motley Fool 21 days ago
Ivonescimab Receives NMPA Approval for First-Line Treatment of PD-L1-Positive NSCLC, Based on Breakthrough Head to Head Phase III Trial Demonstrating Superior Efficacy Over Pembrolizumab

Ivonescimab Receives NMPA Approval for First-Line Treatment of PD-L1-Positive NSCLC, Based on Breakthrough Head to Head Phase III Trial Demonstrating Superior Efficacy Over Pembrolizumab
PR Newswire 21 days ago
FDA approves Akeso’s monoclonal antibody for nasopharyngeal carcinoma

FDA approves Akeso’s monoclonal antibody for nasopharyngeal carcinoma
Pharmaceutical Technology 22 days ago
Akeso Announces FDA Approval for Penpulimab-kcqx in Two BLA Indications for Comprehensive Treatment of Advanced Nasopharyngeal Carcinoma

Akeso Announces FDA Approval for Penpulimab-kcqx in Two BLA Indications for Comprehensive Treatment of Advanced Nasopharyngeal Carcinoma
PR Newswire 22 days ago
Akeso and Summit notch another Phase III win with their Keytruda competitor

Akeso and Summit notch another Phase III win with their Keytruda competitor
Clinical Trials Arena 23 days ago
Why Is Summit Therapeutics Stock Soaring On Wednesday?

Why Is Summit Therapeutics Stock Soaring On Wednesday?
Benzinga 23 days ago
Ivonescimab in Combination with Chemotherapy Demonstrates Statistically Significant and Strongly Positive Results in First-Line Treatment of Squamous Non-Small Cell Lung Cancer (sq-NSCLC) vs. Tislelizumab in Combination with Chemotherapy

Ivonescimab in Combination with Chemotherapy Demonstrates Statistically Significant and Strongly Positive Results in First-Line Treatment of Squamous Non-Small Cell Lung Cancer (sq-NSCLC) vs. Tislelizumab in Combination with Chemotherapy
PR Newswire 24 days ago
Akeso's Ebdarokimab ( IL - 12/IL - 23 Dual - Targeted Monoclonal Antibody) Approved in China for Moderate - to - Severe Plaque Psoriasis

Akeso's Ebdarokimab ( IL - 12/IL - 23 Dual - Targeted Monoclonal Antibody) Approved in China for Moderate - to - Severe Plaque Psoriasis
PR Newswire 29 days ago
3 Asian Stocks Estimated To Be Up To 42.1% Below Intrinsic Value

3 Asian Stocks Estimated To Be Up To 42.1% Below Intrinsic Value
Simply Wall St. 29 days ago
View More

Related Tickers

WINTW WINDTREE THERAPEUTICS INC C/WTS
0.0060
+445.45%
 
AAPG Ascentage Pharma Group Internat
22.65
+0.13%
 
ADAG Adagene Inc.
1.7700
-2.75%
 
ACTU Actuate Therapeutics, Inc. Common stock
10.55
+8.09%
 
1801.HK INNOVENT BIO
51.000
+2.10%
 
ADIL Adial Pharmaceuticals, Inc.
0.6578
-0.33%
 
ACXP Acurx Pharmaceuticals, Inc.
0.3870
+3.73%
 
ACLX Arcellx, Inc.
58.78
+0.56%
 
TRVI Trevi Therapeutics, Inc.
6.50
+5.01%
 
ACRS Aclaris Therapeutics, Inc.
1.3100
+7.38%